Science and Pipelines

Using its internal drug discovery platform, Accendatech has developed some first-in-class therapeutics that are in various development phases.

Candidate indication Pre-clinicale Phase 1 Phase 2 pivotal NDA
ACT001
GBM
DIPG/DMG
IPF/ILD
Brain metastasis
ACT004
Renal fibrosise
ACT006
IBD
ACT009
Sepsis and broad-spetrum antiviral
ACT002
Pancreatic cancer
ACT003
Squamous cell lung carcinoma